Pharmgen Science Inc. has patented H+/K+-ATPase inhibitors that are potentially useful for the treatment of asthma, esophagitis, Helicobacter pylori infection, gastroesophageal reflux disease, gastritis, peptic ulcer and more.
CNCCS SCARL Collezione Nazionale Dei Composti Chimici E Centro Screening and IRBM SpA have patented new serine protease NS3/nonstructural protein 2B (NS3/NS2B) (flavivirus) inhibitors potentially useful for the treatment of West Nile and Zika virus infections.
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have identified new calcitonin receptor (CALCR; CT-R) and amylin receptor dual agonists potentially useful for the treatment of metabolic dysfunction-associated steatohepatitis (MASH; NASH), overweight, dyslipidemia, cognitive and cardiovascular disorders.
The University of Melbourne has reported new radionuclide-drug conjugates (RDCs) comprising copper ion chelated to sarcophagine covalently bound to a peptide-targeting glutamate carboxypeptidase 2 (FOLH1; NAALAD1; PSMA) and another peptide targeting gastrin-releasing peptide receptor (GRPR).
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3 receptor agonists potentially useful for the treatment of neurological and psychiatric disorders.
The University of North Carolina at Chapel Hill has disclosed new large neutral amino acids transporter small subunit 1 (SLC7A5; LAT1) inhibitors reported to be useful for the diagnosis and treatment of cancer.
When it comes to vaccines and preparedness, platform delivery technologies can be both a boon and a barrier. On the one hand, an existing platform can speed development of a vaccine targeting an unexpected viral scare such as the recent Bundibugyo Ebola and Andes hantavirus outbreaks. On the other hand, the intellectual property (IP) protecting that platform adds to the economic hurdles facing smaller vaccine developers, Douglas Bucklin, a life sciences patent attorney with Volpe Koenig, told BioWorld.
Zydus Lifesciences Ltd. has synthesized co-crystals of saroglitazar and chitosan acting as triglyceride-lowering agents found to be potentially useful for the treatment of dyslipidemia and hyperglycemia.
Rin Institute Inc. has disclosed antibody-drug conjugates consisting of an antibody targeting insoluble fibrin conjugated to MMAE through a plasmin-cleavable linker reported to be useful for the treatment of cancer.
Farsight Medical Technology (Shanghai) Co. Ltd. has identified cyclosporin analogues found to be potentially useful for the treatment of hepatitis B viral infections.
RSS
